Organon & Co.
$9.26
▲
3.58%
2026-04-21 08:36:01
www.organon.com
NYQ: OGN
Explore Organon & Co. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.41 B
Current Price
$9.26
52W High / Low
$13.24 / $5.69
Stock P/E
12.89
Book Value
$2.89
Dividend Yield
0.86%
ROCE
11.7%
ROE
30.56%
Face Value
—
EPS
$0.72
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
10,000
Beta
0.64
Debt / Equity
1,170.21
Current Ratio
1.82
Quick Ratio
1.23
Forward P/E
2.37
Price / Sales
0.37
Enterprise Value
$10.52 B
EV / EBITDA
6.36
EV / Revenue
1.69
Rating
Hold
Target Price
$9
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Valuation is not stretched on P/E basis.
Cons
- Leverage is relatively high.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Bristol-Myers Squibb Company | $59.38 | 17.16 | $121.36 B | 4.26% | 20.6% | 40.44% | $62.89 / $42.52 | $9.07 |
| 2. | AstraZeneca PLC | $196.47 | 30 | $305.64 B | 1.58% | 15.97% | 22.84% | $15,730 / $9,651 | $31.38 |
| 3. | MIRA Pharmaceuticals, Inc. | $1.12 | — | $47.06 M | — | -100.98% | -1.66% | $2.45 / $0.83 | $0.25 |
| 4. | AbbVie Inc. | NOT FOUND | 86.59 | $360.82 B | 3.4% | 22.16% | 62.25% | $244.81 / $168.54 | $-1.85 |
| 5. | Scilex Holding Company | $6.95 | — | $58.97 M | — | 55.67% | 39.83% | $34.27 / $3.6 | $-29.75 |
| 6. | Merck & Co., Inc. | $112.83 | 15.49 | $278.33 B | 2.9% | 20.37% | 36.88% | $125.14 / $73.31 | $21.26 |
| 7. | Novo Nordisk A/S | $39.12 | 10.82 | $131.02 B | 4.54% | 39.01% | 60.7% | $533.4 / $224.25 | $6.83 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.51 B | 1.6 B | 1.59 B | 1.51 B | 1.59 B | — |
| Operating Profit | 217 M | 358 M | 326 M | 325 M | 296 M | — |
| Net Profit | -205 M | 160 M | 145 M | 87 M | 109 M | — |
| EPS in Rs | -0.79 | 0.61 | 0.56 | 0.33 | 0.42 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 6.22 B | 6.4 B | 6.26 B | 6.17 B |
| Operating Profit | 1.23 B | 1.49 B | 1.33 B | 1.71 B |
| Net Profit | 187 M | 864 M | 1.02 B | 917 M |
| EPS in Rs | 0.72 | 3.32 | 3.93 | 3.52 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 12.87 B | 13.1 B | 12.06 B | 10.96 B |
| Total Liabilities | 12.12 B | 12.63 B | 12.13 B | 11.85 B |
| Equity | 752 M | 472 M | -70 M | -892 M |
| Current Assets | 4.35 B | 4.35 B | 4.51 B | 3.93 B |
| Current Liabilities | 2.39 B | 2.72 B | 2.92 B | 2.51 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 700 M | 939 M | 799 M | 858 M |
| Investing CF | -390 M | -513 M | -260 M | -420 M |
| Financing CF | -561 M | -368 M | -569 M | -433 M |
| Free CF | 384 M | 588 M | 538 M | 431 M |
| Capex | -316 M | -351 M | -261 M | -427 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 2.24% | 1.44% | — | — |
| Earnings Growth % | -15.54% | 11.56% | — | — |
| Profit Margin % | 13.49% | 16.33% | 14.85% | — |
| Operating Margin % | 23.21% | 21.19% | 27.62% | — |
| Gross Margin % | 58.02% | 59.84% | 62.84% | — |
| EBITDA Margin % | 25.05% | 22.93% | 28.44% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2026-02-23 | $0.02 |
| 2025-11-20 | $0.02 |
| 2025-08-15 | $0.02 |
| 2025-05-12 | $0.02 |
| 2025-02-24 | $0.28 |
Stock Splits
No stock split history available.